Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
P/B ratio for Inhibrx, Inc. (INBX)
P/B ratio as of 2023: 41.17
According to Inhibrx, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 41.17. At the end of 2022 the company had a P/B ratio of 17.02.
P/B ratio history for Inhibrx, Inc. from 2016 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 41.17 |
| 2022 | 17.02 |
| 2021 | 31.69 |
| 2020 | 11.04 |
| 2019 | -8.06 |
| 2018 | -9.69 |
| 2017 | -20.64 |
| 2016 | -81.55 |